Recipharm and Honeywell to speed development of inhalers with a near-zero global warming potential propellant
Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care.Global contract development and manufacturing organisation (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell’s near-zero global warming potential (GWP) propellant. As many as 384 million people globally suffer from chronic obstructive pulmonary disease (COPD), and about 262 million people suffer from asthma.[[[1]]] Many of these